A directory of where to buy chemicals in the USA, including: distributors, industrial manufacturers, bulk supplies and wholesalers of raw ingredients & finished goods.
Search for products or services, then visit the suppliers website for prices or more information.
| Product | Description | |
|---|---|---|
| GSK4112 | GSK 4112, a kind of synthetic agonist of REV-ERBα, could suppress the expression of sorts of genes involved in gluconeogenesis. IC50: 0.4 μM (EC50). Uses: Gsk 4112 is a kind of synthetic agonist of rev-erbα and could suppress the expression of sorts of genes involved in gluconeogenesis. Synonyms: GSK4112; GSK 4112; GSK-4112. SR6452; CHEMBL1961795; 1216744-19-2; MLS006010708; GTPL2903. Grade: 95%. CAS No. 1216744-19-2. Molecular formula: C18H21ClN2O4S. Mole weight: 396.89. |  |
| GSK 4112 | GSK 4112. Group: Biochemicals. Grades: Purified. CAS No. 1216744-19-2. Pack Sizes: 10mg, 50mg. US Biological Life Sciences. |  Worldwide |
| GSK429286A | GSK429286A is a selective inhibitor of ROCK1 with an IC50 value of 14 nM. Uses: Scientific research. Group: Signaling pathways. CAS No. 864082-47-3. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-11000. |  |
| GSK429286A | GSK429286A is a selective inhibitor of ROCK1 and ROCK2 with IC50 of 14 nM and 63 nM, respectively. Uses: Reprogramming, self-renewal. Synonyms: GSK 429286A; GSK-429286A. Grade: 0.98. CAS No. 864082-47-3. Molecular formula: C21H16F4N4O2. Mole weight: 432.37. | |
| GSK4418959 | GSK4418959 (IDE275) is a non-covalent, reversible, selective and orally active WRN helicase inhibitor. GSK4418959 inhibits ATPase and DNA unwinding functions in an ATP-competitive manner. GSK4418959 can be used for the study of microsatellite instability-high (MSI-H) cancer[1]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: IDE275. CAS No. 3064599-36-3. Pack Sizes: 1 mg; 5 mg; 10 mg; 25 mg; 50 mg. Product ID: HY-169422. | |
| GSK461364 | GSK461364 is a selective, reversible and ATP-competitive Polo-like kinase 1 (PLK1) inhibitor with a Ki value of 2.2 nM. Uses: Designed for use in research and industrial production. Additional or Alternative Names: 5-[6-[(4-Methyl-1-piperazinyl)methyl]-1h-benzimidazol-1-yl]-3-[(1r)-1-[2-(trifluoromethyl)phenyl]ethoxy]-2-thiophenecarboxamide. Product Category: Inhibitors. Appearance: White to Beige Powder. CAS No. 929095-18-1. Molecular formula: C27H28N5O2F3S. Mole weight: 543.6. Purity: 0.96. Product ID: ACM929095181. Alfa Chemistry ISO 9001:2015 Certified. |  |
| GSK461364 | GSK461364 is a selective, reversible and ATP-competitive Polo-like kinase 1 (PLK1) inhibitor with a Ki value of 2.2 nM. Uses: Scientific research. Group: Signaling pathways. Alternative Names: GSK461364A. CAS No. 929095-18-1. Pack Sizes: 10 mM * 1 mL; 1 mg; 5 mg; 10 mg; 50 mg; 100 mg; 200 mg. Product ID: HY-50877. | |
| GSK-461364 | GSK-461364 is a Polo-like kinase 1 inhibitor, is also a small molecule Polo-like kinase 1 (PLK1) inhibitor with potential antineoplastic activity. Polo-like kinase 1 inhibitor GSK461364 selectively inhibits Plk1, inducing selective G2/M arrest followed by apoptosis in a variety of tumor cells while causing reversible cell arrest at the G1 and G2 stage without apoptosis in normal cells. Plk1, named after the polo gene of Drosophila melanogaster, is a serine/threonine protein kinase involved in regulating mitotic spindle function in a non-ATP competitive manner. Uses: Designed for use in research and industrial production. Additional or Alternative Names: GSK461364; GSK 461364; GSK-461364; GSK461364A; GSK 461364A; GSK-461364A. Product Category: Inhibitors. Appearance: White solid powder. CAS No. 929095-18-1. Molecular formula: C27H28F3N5O2S. Mole weight: 543.6. Purity: >98%. IUPACName: (R)-5-(6-((4-methylpiperazin-1-yl)methyl)-1H-benzo[d]imidazol-1-yl)-3-(1-(2-(trifluoromethyl)phenyl)ethoxy)thiophene-2-carboxamide. Canonical SMILES: O=C(C1=C(O[C@@H](C2=CC=CC=C2C(F)(F)F)C)C=C(N3C=NC4=CC=C(CN5CCN(C)CC5)C=C34)S1)N. Product ID: ACM929095181-2. Alfa Chemistry ISO 9001:2015 Certified. | |
| GSK-461364 | GSK-461364 is a Polo-like kinase 1 inhibitor, is also a small molecule Polo-like kinase 1 (PLK1) inhibitor with potential antineoplastic activity. Polo-like kinase 1 inhibitor GSK461364 selectively inhibits Plk1, inducing selective G2/M arrest followed by apoptosis in a variety of tumor cells while causing reversible cell arrest at the G1 and G2 stage without apoptosis in normal cells. Plk1, named after the polo gene of Drosophila melanogaster, is a serine/threonine protein kinase involved in regulating mitotic spindle function in a non-ATP competitive manner. Synonyms: GSK461364; GSK 461364; GSK-461364; GSK461364A; GSK 461364A; GSK-461364A. 5-[6-[(4-Methyl-1-piperazinyl)methyl]-1h-benzimidazol-1-yl]-3-[(1r)-1-[2-(trifluoromethyl)phenyl]ethoxy]-2-thiophenecarboxamide. CAS No. 929095-18-1. Molecular formula: C27H28F3N5O2S. Mole weight: 543.609. | |
| GSK461364A | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. |  |
| GSK 461364 analogue I | GSK 461364 analogue I is a potent polo-like kinase (PLK) inhibitor with selectivity for PLK1 (IC50: 2 nM) over PLK3 (IC50: 630 nM). Synonyms: GSK 461364 analogue I; GSK461364 analogue I; GSK-461364 analogue I; GSK579289A; GSK 579289A; GSK-579289A. Compound 25 [PMID 19237286]; 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-(1-methylpiperidin-4-yl)oxybenzimidazol-1-yl]thiophene-2-carboxamide. Grade: 99%. CAS No. 929095-23-8. Molecular formula: C26H27ClN4O3S. Mole weight: 511.04. | |
| GSK 461364 analogue II | GSK 461364 analogue II is a potent polo-like kinase (PLK) inhibitor with selectivity for PLK1 (IC50: 2 nM) over PLK3 (IC50: 270 nM). Synonyms: GSK 461364 analogue II; GSK461364 analogue II; GSK-461364 analogue II; 5-[6-(1-methylpiperidin-4-yl)oxybenzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]thiophene-2-carboxamide. Grade: 99%. CAS No. 929095-22-7. Molecular formula: C27H27F3N4O3S. Mole weight: 544.59. | |
| GSK466317A | GSK466317A is a G-Protein-Coupled Receptor Kinase 2 (GRK2) Inhibitor. Synonyms: GSK466317A; GSK-466317A; GSK 466317A. N-(7-chloro-1H-indazol-5-yl)-6-methyl-2-oxo-4-[4-(trifluoromethyl)phenyl]-3,4-dihydro-1H-pyridine-5-carboxamide. Grade: 98%. CAS No. 864082-48-4. Molecular formula: C21H16ClF3N4O2. Mole weight: 448.83. | |
| GSK467 | GSK467 is a cell penetrant and selective inhibitor of KDM5B (JARID1B/PLU1) with Ki of 10 nM. Synonyms: GSK-467; GSK 467. CAS No. 1628332-52-4. Molecular formula: C17H13N5O2. Mole weight: 319.32. | |
| GSK467 | GSK467 is a cell penetrant and selective KDM5B (JARID1B or PLU1) inhibitor with a Ki of 10 nM and an IC50 of 26 nM. GSK467 shows 180-fold selectivity for KDM4C and no measurable inhibitory effects toward KDM6 or other Jumonji family members[1][2]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1628332-52-4. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-116761. | |
| GSK 4716 | GSK 4716 is a selective agonist of estrogen-related receptors ERRβ and ERRγ displaying selectivity over ERRα and the classical estrogen receptors. Activation of GSK 4716 regulates mitochondrial activity in skeletal muscle during exercise. Synonyms: GSK4716; GSK 4716; GSK-4716; 4-Hydroxy-2-[(1E)-[4-(1-methylethyl)phenyl]methylene]hydrazide. Grade: ≥99% by HPLC. CAS No. 101574-65-6. Molecular formula: C17H18N2O2. Mole weight: 282.34. | |
| GSK 4716 | GSK 4716. Group: Biochemicals. Grades: Purified. CAS No. 101574-65-6. Pack Sizes: 10mg, 50mg. US Biological Life Sciences. | Worldwide |
| GSK481 | GSK481 is a potent inhibitor of Receptor-interacting serine/threonine-protein kinase 1 (RIPK1 or RIP1; IC50 value 2.8 nM for inhibition of Ser166 autophosphorylation of hWT RIP1) with preference for RIP1 over 450 other kinases. Synonyms: GSK481; GSK-481; GSK 481. 5-benzyl-N-[(3S)-5-methyl-4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-1,2-oxazole-3-carboxamide. Grade: 98%. CAS No. 1622849-58-4. Molecular formula: C21H19N3O4. Mole weight: 377.39. | |
| GSK484 | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| GSK-484 | GSK-484 is a potent protein-arginine deiminase type-4 (PAD-4) inhibitor. Synonyms: GSK484; GSK 484. Grade: ≥98% by HPLC. CAS No. 1652629-23-6. Molecular formula: C27H31N5O3. Mole weight: 473.6. | |
| GSK-484 hydrochloride | GSK-484, a benzoimidazole derivative, has been found to be an effective reversible PAD-4 inhibitor that could be significant in some inflammation and immune response studies and probably have potential activities in anticancer studies. IC50: 50nM (without calcium), 250 nM (2 mM calcium exists). Synonyms: GSK484; GSK 484; GSK-484; ((3S,4R)-3-Amino-4-hydroxypiperidin-1-yl)(2-(1-(cyclopropylmethyl)-1H-indol-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazol-5-yl)methanone hydrochloride. Grade: 98%. CAS No. 1652591-81-5. Molecular formula: C27H32ClN5O3. Mole weight: 510.04. | |
| GSK484 hydrochloride | GSK484 hydrochloride is a selective and reversible peptidylarginine deiminase 4 (PAD4) inhibitor. GSK484 hydrochloride demonstrates high affinity binding to PAD4 with IC50s of 50 nM in the absence of Calcium. In the presence of 2 mM Calcium, notably lower potency (250 nM) is observed. Uses: Scientific research. Group: Signaling pathways. CAS No. 1652591-81-5. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg; 200 mg; 500 mg. Product ID: HY-100514. | |
| GSK494581A | GSK494581A, a specific ligand for human GPR55 (pEC50 of 6.8), acts as an inhibitor of glycine transporter subtype 1 (GlyT1). Synonyms: GSK 494581A; GSK-494581A. CAS No. 909416-67-7. Molecular formula: C27H28F2N2O4S. Mole weight: 514.58. | |
| GSK-503 | GSK-503 is a potent EZH2 inhibitor with potential anticancer activity. Increased activity of the epigenetic modifier EZH2 has been associated with different cancers. Synonyms: GSK503; GSK 503; GSK503. Grade: 98%. CAS No. 1346572-63-1. Molecular formula: C31H38N6O2. Mole weight: 526.67. | |
| GSK5182 | GSK5182 is a small-molecule ERRγ inverse agonist, which inhibited pro-inflammatory cytokine-induced catabolic factors in mouse articular chondrocytes. Synonyms: GSK-5182; GSK 5182. CAS No. 877387-37-6. Molecular formula: C27H31NO3. Mole weight: 417.54. | |
| GSK5182 | GSK5182 is a specific inverse agonist for estrogen-related receptor γ. Uses: Designed for use in research and industrial production. Additional or Alternative Names: GSK5182; GSK 5182; GSK-5182. Product Category: Agonists. Appearance: Solid powder. CAS No. 877387-37-6. Molecular formula: C27H31NO3. Mole weight: 417.55. Purity: >98%. IUPACName: 4-[(Z)-1-[4-(2-dimethylaminoethoxy)phenyl]-5-hydroxy-2-phenylpent-1-enyl]phenol. Canonical SMILES: OC1=CC=C(/C(C2=CC=C(OCCN(C)C)C=C2)=C(C3=CC=CC=C3)\CCCO)C=C1. Product ID: ACM877387376. Alfa Chemistry ISO 9001:2015 Certified. | |
| GSK525762 | GSK525762A, also known as I-BET-762 and GSK525762, is a small molecule inhibitor of the BET (Bromodomain and Extra-Terminal) family of bromodomain-containing proteins with potential antineoplastic activity. Upon administration, the BET inhibitor GSK525762 binds to the acetylated lysine recognition motifs on the bromodomain of BET proteins, thereby preventing the interaction between the BET proteins and acetylated histone peptides. This disrupts chromatin remodeling and gene expression. Prevention of the expression of certain growth-promoting genes may lead to an inhibition of tumor cell growth. Characterized by a tandem repeat of bromodomain at the N-terminus, BET proteins, comprising of BRD2, BRD3, BRD4 and BRDT, are transcriptional regulators that play an important role during development and cellular growth. Synonyms: GSK525762; GSK525762; GSK525762; GSK525762A; GSK-525762A; GSK 525762A; I-BET-762; I-BET762; I-BET 762; molibresib. CAS No. 1260907-17-2. Molecular formula: C22H22ClN5O2. Mole weight: 423.9. | |
| GSK 525762A | GSK 525762A. Group: Biochemicals. Alternative Names: (4S)-6-(4-Chlorophenyl)-N-ethyl-8-methoxy-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine-4-acetamide; I-BET 762. Grades: Highly Purified. CAS No. 1260907-17-2. Pack Sizes: 5mg. Molecular Formula: C22H22ClN5O2, Molecular Weight: 423.9. US Biological Life Sciences. | Worldwide |
| GSK 525762A-d5 | GSK 525762A-d5. Group: Biochemicals. Alternative Names: (4S)-6-(4-Chlorophenyl)-N-ethyl-8-methoxy-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine-4-acetamide-d5; I-BET 762-d5. Grades: Highly Purified. Pack Sizes: 1mg. Molecular Formula: C22H17D5ClN5O2, Molecular Weight: 428.93. US Biological Life Sciences. | Worldwide |
| GSK 525768A | GSK 525768A is a enantiomer analogue of GSK 525762A which is a BET family inhibitor aiming at the bromodomain and has potential effect against cancers and sorts of other diseases related to BET bromodomains. Uses: Gsk 525768a is a enantiomer analogue of gsk 525762a which is a bet family inhibitor aiming at the bromodomain and has potential effect against cancers and sorts of other diseases related to bet bromodomains. Synonyms: GSK 525768A; GSK525768A; GSK-525762A; CHEMBL2153435; SCHEMBL12966358; DTXSID50680634. Grade: 98%. CAS No. 1260530-25-3. Molecular formula: C22H22ClN5O2. Mole weight: 423.90. | |
| GSK547 | GSK547 is a highly selective and potent RIP1 (RIPK1) inhibitor which displays 400-fold improvement in mouse pharmacokinetic oral exposure compared with GSK963. Synonyms: RIP1i. Grade: ≥98%. CAS No. 2226735-55-1. Molecular formula: C20H18F2N6O. Mole weight: 396.39. | |
| GSK547 | GSK547 (GSK'547) is a highly selective and potent inhibitor of receptor-interacting serine/threonine protein kinase 1 (RIPK1), inhibits macrophage-mediated adaptive immune tolerance in pancreatic cancer[1]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: GSK'547. CAS No. 2226735-55-1. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg; 200 mg. Product ID: HY-114492. | |
| GSK-5498A | GSK-5498A, a CRAC channel blocker, has been found to have effect in restraining pro-inflammatory cytokine. IC50: 1 uM. Uses: Gsk-5498a is a crac channel blocker that has been found to have effect in restraining pro-inflammatory cytokine. Synonyms: GSK-5498A; GSK5498A; GSK 5498A; 2,6-Difluoro-N-(1-(2-fluoro-6-(trifluoromethyl)benzyl)-1H-pyrazol-3-yl)benzamide. Grade: 97%. CAS No. 1253186-49-0. Molecular formula: C18H11F6N3O. Mole weight: 399.29. | |
| GSK554418A | GSK-554418A is a azaindole Cannabinoid receptor type 2 (CB2) agonist. It can be used for the treatment of chronic pain. Uses: Chronic pain. Synonyms: GSK-554418A; GSK 554418A; GSK554418A. (4-((3-chlorophenyl)amino)-1-methyl-1H-pyrrolo(3,2-C)pyridin-7-yl)-4-morpholinyl- Methanone. Grade: 98%. CAS No. 871819-90-8. Molecular formula: C19H19ClN4O2. Mole weight: 370.84. | |
| GSK572A | GSK572A is a new and powerful EchA6 potent inhibitor that can be used to treat pulmonary tuberculosis. Synonyms: (5R,7S)-5-(4-Ethylphenyl)-N-[(5-Fluoropyridin-2-yl)methyl]-7-(Trifluoromethyl)-4,5,6,7-Tetrahydropyrazolo[1,5-A]pyrimidine-3-Carboxamide. Grade: >98.0%. CAS No. 1403602-32-3. Molecular formula: C22H21F4N5O. Mole weight: 447.44. | |
| GSK575594A | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| GSK583 | GSK583 is a selective receptor-interacting serine/threonine-protein kinase 2 (RIP2 Kinase) inhibitor and the RIP2K binding IC50 is 5 nM. GSK583 can inhibit both TNF-α and IL-6 production with an IC50 value of 200 nM in an ex vivo human translational model. Synonyms: GSK583; GSK 583; GSK-583. 6 - (tert-Butylsulfonyl) - N - (5-fluoro - 1H - indazol-3-yl)quinolin-4-amine. Grade: 98%. CAS No. 1346547-00-9. Molecular formula: C20H19FN4O2S. Mole weight: 398.46. | |
| GSK583 | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| GSK583 | GSK583 is a highly potent, orally active and selective inhibitor of RIP2 Kinase, with IC50 of 5 nM. GSK583 inhibits both TNF-? and IL-6 production with an IC50 value of 200 nM. Uses: Scientific research. Group: Signaling pathways. CAS No. 1346547-00-9. Pack Sizes: 10 mM * 1 mL; 2 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-100339. | |
| GSK591 | ?97% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| GSK591 | GSK591 (EPZ015866) is a potent and selective inhibitor of protein methyltransferase 5 (PRMT5) with an IC50 of 4 nM[1]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: EPZ015866; GSK3203591. CAS No. 1616391-87-7. Pack Sizes: 10 mM * 1 mL; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-100235. | |
| GSK591 | GSK591, also known as EPZ015866 and GSK3203591, is a chemical probe for PRMT5. In an in vitro biochemical assay, GSK591 potently inhibits the PRMT5/MEP50 complex from methylating (histone) H4 with IC50=11 nM. In Z-138 cells, GSK591 inhibits the symmetric arginine methylation of SmD3 with EC50=56 nM. Further, GSK591 is selective for PRMT5 (up to 50 micromolar) relative to a panel of methyltransferases. (http://www.thesgc.org/chemical-probes/GSK59). Uses: Designed for use in research and industrial production. Additional or Alternative Names: GSK591; GSK-591; GSK 591; EPZ015866; EPZ-015866; EPZ 015866; GSK 3203591; GSK-3203591; GSK3203591. Product Category: Others. Appearance: Solid powder. CAS No. 1616391-87-7. Molecular formula: C22H28N4O2. Mole weight: 380.49. Purity: >98%. IUPACName: (S)-2-(cyclobutylamino)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)isonicotinamide. Canonical SMILES: O=C(NC[C@H](O)CN1CCC(C=CC=C2)=C2C1)C3=CC(NC4CCC4)=NC=C3. Product ID: ACM1616391877. Alfa Chemistry ISO 9001:2015 Certified. Categories: GSK-598809. | |
| GSK5959 | GSK-5959 is a potent, selective and cell permeable BRPF1 bromodomain inhibitor with IC50 value of 80 nM. It exhibits >100-fold selectivity for BRPF1 over a panel of 35 other bromodomains, including BRPF2/3 and BET family bromodomains. It is used at 10 μM final concentration in various in vitro assays. It disrupts chromatin binding of BRPF1 in a cellular assay by blocking the interaction of BRPF1 with histone H3 in vitro. Uses: Gsk-5959 disrupts chromatin binding of brpf1 in a cellular assay. Synonyms: N-(1,3-dimethyl-2-oxo-6-piperidin-1-ylbenzimidazol-5-yl)-2-methoxybenzamide; GSK-5959; GSK 5959; GSK5959. Grade: >98%. CAS No. 901245-65-6. Molecular formula: C22H26N4O3. Mole weight: 394.47. | |
| GSK 5959 | GSK 5959. Group: Biochemicals. Grades: Purified. CAS No. 901245-65-6. Pack Sizes: 10mg, 50mg. US Biological Life Sciences. | Worldwide |
| GSK598809 | GSK598809 is a potent and selective antagonist of dopamine D3 Receptor (DRD3), with a pKi of 8.9. Synonyms: 5-(5-(3-(1-(2-fluoro-4-(trifluoromethyl)phenyl)-3-azabicyclo[3.1.0]hexan-3-yl)propylthio)-4-methyl-4H-1,2,4-triazol-3-yl)-4-methyloxazole; 3-Azabicyclo[3.1.0]hexane, 1-[2-fluoro-4-(trifluoromethyl)phenyl]-3-[3-[[4-methyl-5-(4-methyl-5-oxazolyl)-4H-1,2,4-triazol-3-yl]thio]propyl]-; 1-[2-Fluoro-4-(trifluoromethyl)phenyl]-3-(3-{[4-methyl-5-(4-methyl-1,3-oxazol-5-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}propyl)-3-azabicyclo[3.1.0]hexane. Grade: ≥95%. CAS No. 863680-45-9. Molecular formula: C22H23F4N5OS. Mole weight: 481.51. | |
| GSK-598809 | GSK598809 is a selective Dopamine D3 receptor antagonist originated by GlaxoSmithKline. It may decrease the rewarding effects of contextual cues associated with drug intake preclinically and that may reduce drug craving in humans. No recent development for the treatment of Drug abuse. Eating disorders and Smoking withdrawal was reported. Uses: Drug abuse; eating disorders; smoking withdrawal. Synonyms: GSK-598809; GSK 598809; GSK598809; NII-Y5OZ63HC3V; 5-(5-((3-((1S,5R)-1-(2-Fluoro-4-(trifluoromethyl)phenyl)-5-methyl-3-azabicyclo(3.1.0)hexan-3-yl)propyl)thio)-4-methyl-4H-1,2,4-triazol-3-yl)-4-methyloxazole. Grade: 98%. CAS No. 1310803-30-5. Molecular formula: C23H25F4N5OS. Mole weight: 495.54. | |
| GSK620 | GSK620 is a potent, selective and orally active pan-BD2 inhibitor. GSK620 shows an anti-inflammatory phenotype in human whole blood. GSK620 reduces the MCP-1 response in a concentration-dependent manner with (an expected) ?1 log drop off in potency relative to the biochemical BRD4 BD2 potencies observed. Synonyms: QCZ. CAS No. 2088410-46-0. Molecular formula: C18H19N3O3. Mole weight: 325.36. | |
| GSK620 | GSK620 is a potent and orally active pan-BD2 inhibitor with excellent broad selectivity, developability and in vivo oral pharmacokinetics. GSK620 is highly selective for the BET-BD2 family of proteins, with >200-fold selectivity over all other bromodomains. GSK620 shows an anti-inflammatory phenotype in human whole blood[1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 2088410-46-0. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-137892. | |
| GSK621 | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| GSK621 | GSK621 is an activator of AMP-activated protein kinase (AMPK). GSK621 induces autophagy and apoptosis. GSK621 induces eiF2α phosphorylation-a hallmark of UPR activation. Synonyms: GSK-621; GSK 621. Grade: 98%. CAS No. 1346607-05-3. Molecular formula: C26H20ClN3O5. Mole weight: 489.91. | |
| GSK621 | GSK621 is a specific AMPK activator, with IC50 values of 13-30 ?M for AML cells. GSK621 induces autophagy and apoptosis. GSK621 induces eiF2? phosphorylation-a hallmark of UPR activation[1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1346607-05-3. Pack Sizes: 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-100548. | |
| GSK-626616 | GSK-626616 is a potent, orally bioavailable inhibitor of DYRK3 (IC50=0.7 nM). GSK-626616 inhibits other members of the DYRK family (e.g., DYRK1A and DYRK2) with similar potency, which is a potential therapy for the treatment of anemia[1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1025821-33-3. Pack Sizes: 10 mM * 1 mL; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-105309. | |
| GSK-626616 | GSK-626616 is a YAK3/DYRK3 kinase inhibitor. It is a chemoprotective agent for the potential treatment of chemotherapy-induced anaemia. Uses: Gsk-626616 is a chemoprotective agent for the potential treatment of chemotherapy-induced anaemia. Synonyms: GSK-626616; GSK 626616; GSK626616; (5Z)-2-(2,6-Dichloroanilino)-5-(quinoxalin-6-ylmethylidene)-1,3-thiazolone; GSK626616; (5Z)-2-(2,6-dichloroanilino)-5-(quinoxalin-6-ylmethylidene)-1,3-thiazol-4-one. Grade: >98 %. CAS No. 1025821-33-3. Molecular formula: C18H10Cl2N4OS. Mole weight: 401.26. | |
| GSK650394 | GSK650394 is a competitive inhibitor that quantitatively blocks the effect of androgens on LNCaP cell growth. Synonyms: GSK650394; GSK-650394; GSK 650394. Grade: 0.98. CAS No. 890842-28-1. Molecular formula: C25H22N2O2. Mole weight: 382.45. | |
| GSK 650394 | GSK 650394 is a novel SGK inhibitor with IC 50 of 62 nM and 103 nM for SGK1 and SGK2 in the SPA assay respectively. GSK 650394 also inhibits influenza virus replication. Uses: Scientific research. Group: Signaling pathways. CAS No. 890842-28-1. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg. Product ID: HY-15192. | |
| GSK 650394 | GSK 650394 Inhibitor. Uses: Scientific use. Product Category: T2622. CAS No. 890842-28-1. |  |
| GSK-650394 | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| GSK656 | GSK656 is a potent inhibitor of Mycobacterium tuberculosis (Mtb) leucyl-tRNA synthetase (LeuRS), with an IC50 of 0.2 μM. Synonyms: Ethanol, 2-(((3S)-3-(aminomethyl)-4-chloro-1,3-dihydro-1-hydroxy-2,1-benzoxaborol-7-yl)oxy)-, hydrochloride (1:1). Grade: 99%. CAS No. 2131798-13-3. Molecular formula: C10H14BCl2NO4. Mole weight: 293.94. | |
| GSK682753A | GSK682753A is a selective and highly potent inverse agonist of the epstein-barr virus-induced receptor 2 (EBI2) with an IC50 of 53.6 nM. Uses: Scientific research. Group: Signaling pathways. CAS No. 1334294-76-6. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-101192. | |
| GSK6853 | GSK6853 is a potent (pKd 9.5), soluble, cell active (20 nM), and highly selective inhibitor of the BRPF1 bromodomain with greater than 1600-fold selectivity over all other bromodomains tested. Synonyms: N-[1,3-dimethyl-6-[(2R)-2-methylpiperazin-1-yl]-2-oxobenzimidazol-5-yl]-2-methoxybenzamide; GSK6853; GSK-6853; GSK-6853. Grade: >98%. CAS No. 1910124-24-1. Molecular formula: C22H27N5O3. Mole weight: 409.49. | |
| GSK6853 | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| GSK690693 | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| GSK-690693 | GSK690693 is a pan-AKT kinase inhibitor, is also an aminofurazan-derived inhibitor of Akt kinases with potential antineoplastic activity. Pan-AKT kinase inhibitor GSK-690693 binds to and inhibits Akt kinases 1, 2, and 3, which may result in the inhibition of protein phosphorylation events downstream from Akt kinases in the PI3K/Akt signaling pathway, and, subsequently, the inhibition of tumor cell proliferation and the induction of tumor cell apoptosis. In addition, this agent may inhibit other protein kinases including protein kinase C (PKC) and protein kinase A (PKA). As serine/threonine protein kinases which are involved in a number of biological processes, AKT kinases promote cell survival by inhibiting apoptosis and are required for glucose transport. Synonyms: GSK-690693; GSK690693. CAS No. 937174-76-0. Molecular formula: C21H27N7O3. Mole weight: 425.48418. | |
| GSK-690693 | GSK-690693 is an ATP-competitive pan-Akt inhibitor with IC50s of 2 nM, 13 nM, 9 nM for Akt1, Akt2 and Akt3, respectively. GSK-690693 is also an AMPK inhibitor, affects Unc-51-like autophagy activating kinase 1 (ULK1) activity and robustly inhibits STING-dependent IRF3 activation[1][2][3]. Uses: Scientific research. Group: Signaling pathways. CAS No. 937174-76-0. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-10249. | |
| GSK 690 Hydrochloride | GSK 690 Hydrochloride is a reversible lysine specific demethylase 1 (LSD1) inhibitor, with a Kd of 9 nM and a biochemical IC50 of 37 nM. Synonyms: 4-{2-(4-Methylphenyl)-5-[(3R)-3-pyrrolidinylmethoxy]-3-pyridinyl}benzonitrile hydrochloride (1:1); Benzonitrile, 4-[2-(4-methylphenyl)-5-[(3R)-3-pyrrolidinylmethoxy]-3-pyridinyl]-, hydrochloride (1:1). Grade: ≥95%. Molecular formula: C24H24ClN3O. Mole weight: 405.92. | |
| GSK-693 | A novel direct InhA inhibitor of Mtb (IC50 = 7 nM). Synonyms: (S)-1-(4-Methylthiazol-2-yl)-1-(5-((1-((2-methylthiazol-4-yl)methyl)-1H-pyrazol-3-yl)amino)-1,3,4-thiadiazol-2-yl)ethan-1-ol. CAS No. 1372891-37-6. Molecular formula: C16H17N7OS3. Mole weight: 419.55. | |
| GSK717 | GSK717 is a potent and selective NOD2 inhibitor. It inhibits muramyl dipeptide (MDP)-induced NOD2-mediated signaling, with an IC50 of 400 nM for MDP-stimulated IL-8 secretion in HEK293/hNOD2 cells. Grade: 99%. CAS No. 1595278-21-9. Molecular formula: C28H28N4O2. Mole weight: 452.55. | |
| GSK717 | GSK717 is a potent, selective NOD2 (nucleotide-binding oligomerization domain 2) inhibitor. GSK717 inhibits muramyl dipeptide (MDP)-induced NOD2-mediated signaling, with an IC50 of 400 nM for MDP-stimulated IL-8 secretion in HEK293/hNOD2 cells[1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1595278-21-9. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-136555. | |
| GSK-7186 | GSK-7186 is a novel inhibitor of HIV integrase that is used for the treatment of Non-cross-resistant HIV infection. Uses: The treatment of non-cross-resistant hiv infection. Synonyms: GSK7186; GSK 7186. | |
| GSK7227 | GSK7227 is a novel class of PPARdelta partial agonists. It shows potent partial agonism of the PPARdelta target genes CPT1a and PDK4 in skeletal muscle cells. Synonyms: GSK-7227; GSK7227; GSK 7227; 2-[[3-(5-Methoxy-4-methylindol-1-yl)sulfonylbenzoyl]amino]-5-methylbenzoic acid; GSK-7227; Benzoic acid, 2-((3-((5-methoxy-4-methyl-1H-indol-1-yl)sulfonyl)benzoyl)amino)-5-methyl-. Grade: >98%. CAS No. 1067214-81-6. Molecular formula: C25H22N2O6S. Mole weight: 478.52. | |
Our database is helping our users find suppliers everyday.
